Profile data is unavailable for this security.
About the company
Chengdu Easton Biopharmaceuticals Co Ltd is a China-based company mainly engaged in the research and development, production and sales of chemical raw materials and chemical pharmaceutical preparations. The Company's main products are chemical generic drugs. Its products include nalmefene hydrochloride injection, caffeine citrate injection, ibuprofen injection, bisoprolol fumarate tablets, ubenimex, etc. Its products are used in the fields of anesthesia and analgesia, cardiovascular, anti-tumor, digestion and children's medicine. The Company operates its businesses within the China market and to overseas markets such as Russia, Switzerland, Tunisia, Germany, South Korea and Japan.
- Revenue in CNY (TTM)1.15bn
- Net income in CNY240.60m
- Incorporated2009
- Employees1.40k
- LocationChengdu Easton Biopharmaceuticals Co LtdNo. 8 Ankang Road, Shuangliu DistrictCHENGDU 610219ChinaCHN
- Phone+86 2 886106668
- Fax+86 2 862321999
- Websitehttp://www.eastonpharma.cn
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zhejiang Ausun Pharmaceutical Co Ltd | 855.13m | 272.71m | 5.98bn | 1.17k | 21.89 | 2.64 | -- | 6.99 | 0.4604 | 0.4604 | 1.44 | 3.82 | 0.2876 | 1.21 | 3.71 | 728,389.90 | 9.17 | 9.38 | 12.29 | 12.84 | 54.14 | 53.09 | 31.89 | 27.14 | 1.96 | -- | 0.1592 | 23.53 | 6.83 | 27.35 | 7.87 | 42.07 | 24.32 | 50.50 |
| Chengdu Easton Biopharmaceuticals Co Ltd | 1.15bn | 240.60m | 6.17bn | 1.40k | 25.54 | 2.33 | -- | 5.34 | 2.01 | 2.01 | 9.65 | 22.07 | 0.3566 | 1.54 | 7.73 | 824,469.80 | 7.43 | 8.72 | 9.15 | 10.64 | 77.92 | 85.10 | 20.84 | 19.16 | 2.59 | -- | 0.0861 | 26.80 | -4.56 | 7.76 | -8.09 | 10.91 | 17.99 | -- |
| Shandong Lukang Pharmaceutical Co Ltd | 6.28bn | 267.79m | 6.23bn | 6.48k | 23.76 | 1.69 | -- | 0.9921 | 0.292 | 0.292 | 6.88 | 4.11 | 0.7187 | 3.54 | 6.45 | 967,865.70 | 3.21 | 2.21 | 5.51 | 4.05 | 23.55 | 23.41 | 4.47 | 3.46 | 0.7313 | 5.39 | 0.4689 | 31.79 | 9.34 | 13.04 | 78.37 | 8.81 | -16.95 | 23.94 |
| JiangSu WuZhong Pharmactcl Devlpm Co Ltd | 2.33bn | -95.04m | 6.43bn | 1.05k | -- | 3.63 | -- | 2.76 | -0.1335 | -0.1335 | 3.22 | 2.48 | 0.553 | 16.07 | 2.29 | 2,220,525.00 | -2.31 | -2.92 | -4.78 | -5.30 | 22.41 | 28.14 | -4.18 | -5.77 | 1.22 | -0.3232 | 0.5063 | -- | 10.55 | 5.65 | 5.58 | -- | -19.08 | -- |
| Cisen Pharmaceutical Co Ltd | 4.48bn | 528.35m | 6.46bn | 3.40k | 12.26 | 1.10 | -- | 1.44 | 1.16 | 1.16 | 9.86 | 13.02 | 0.6082 | 2.81 | 5.65 | 1,315,959.00 | 7.21 | 6.94 | 9.02 | 8.56 | 57.33 | 56.27 | 11.85 | 10.77 | 3.12 | -- | 0.0373 | 33.42 | 9.75 | 3.22 | 48.92 | 0.697 | -15.19 | 10.72 |
| Beijing Foyou Pharma Co Ltd | 3.32bn | 507.64m | 6.58bn | 3.44k | 12.91 | 1.87 | -- | 1.98 | 1.06 | 1.06 | 6.95 | 7.35 | 0.7482 | 3.46 | 9.58 | 967,165.90 | 11.50 | -- | 14.81 | -- | 65.14 | -- | 15.37 | -- | 2.99 | -- | 0.0316 | -- | 3.07 | -- | 11.36 | -- | -- | -- |
| Harbin Pharmaceutical Group Co., Ltd. | 15.67bn | 449.71m | 6.63bn | 9.85k | 14.39 | 1.35 | -- | 0.4232 | 0.1827 | 0.1827 | 6.34 | 1.95 | 1.13 | 6.35 | 3.46 | 1,590,093.00 | 3.79 | 0.7414 | 10.20 | 1.89 | 26.30 | 23.87 | 3.35 | 0.7294 | 1.06 | 40.41 | 0.393 | 0.00 | 11.93 | 7.41 | -14.88 | 2.69 | -5.38 | -- |
| Shouyao Holdings Co Ltd | 5.23m | -191.79m | 6.67bn | 185.00 | -- | 6.89 | -- | 1,274.99 | -1.29 | -1.29 | 0.0352 | 6.51 | 0.0045 | 0.2644 | 5.25 | 28,265.68 | -16.55 | -37.24 | -18.01 | -42.63 | 96.50 | 96.03 | -3,667.74 | -2,251.77 | 8.49 | -- | 0.0018 | -- | 186.18 | -23.51 | -6.76 | -- | 34.59 | -- |
Data as of Jun 25 2024. Currency figures normalised to Chengdu Easton Biopharmaceuticals Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
14.44%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Guotai Asset Management Co., Ltd.as of 31 Dec 2023 | 8.48m | 9.98% |
| Chang Xin Asset Management Co., Ltd.as of 31 Dec 2023 | 1.28m | 1.50% |
| CIB Fund Management Co., Ltd.as of 31 Dec 2023 | 741.44k | 0.87% |
| Great Wall Fund Management Co., Ltd.as of 31 Dec 2023 | 469.86k | 0.55% |
| Essence Fund Co., Ltd.as of 31 Dec 2023 | 346.08k | 0.41% |
| Bosera Asset Management Co., Ltd.as of 31 Dec 2023 | 249.12k | 0.29% |
| Bank of China Investment Management Co., Ltd.as of 31 Dec 2023 | 210.00k | 0.25% |
| BOC International China Ltd. (Investment Management)as of 31 Dec 2023 | 180.00k | 0.21% |
| Lion Fund Management Co., Ltd.as of 31 Dec 2023 | 169.02k | 0.20% |
| Changsheng Fund Management Co., Ltd.as of 31 Dec 2023 | 146.17k | 0.17% |
More ▼
Data from 31 Dec 2023 - 17 Jun 2024Source: FactSet Research Systems Inc.
